Abstracts tagged "RANK/RANKL pathway"

Abstract Number: 390 • 2017 ACR/ARHP Annual Meeting
S-110483, a Novel and Selective EP4 Receptor Antagonist with Anti-Bone Destruction Activities
Toshitaka Ochiai¹, Takashi Maeda², Toshie Nagayasu-Tanaka², Jun Anzai¹, Daiki Kato¹, Yuta Morisaki², Kiyoharu Ukai² and Masahiro Suda², ¹Kaken Pharmaceutical Co., LTD, Kyoto, Japan, ²Pharmacology Department, Kaken Pharmaceutical Co., LTD, Kyoto, Japan
Background/Purpose: S-110483 is our novel potent and selective EP4 receptor (EP4) antagonist. In addition to the well-known fact that EP4 antagonists have anti-inflammatory effects, it…
Abstract Number: 955 • 2017 ACR/ARHP Annual Meeting
In Vitro Effects of CR6086, a Potent ProstaglandinE2 Subtype 4 Receptor Antagonist, on Bone Erosive Pathways
Tiziana Piepoli¹, Mario Montagna¹, Daniele Maggioni¹, Silvia Zerbi¹, Laura Mennuni¹, Marco Lanza¹, Gianfranco Caselli¹ and Lucio C. Rovati², ¹Rottapharm Biotech, Monza, Italy, ²Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: CR6086 is a selective EP4 receptor antagonist immunomodulator in clinical development for rheumatoid arthritis (RA). In animal models of RA, it demonstrated a superior…
Abstract Number: 1126 • 2017 ACR/ARHP Annual Meeting
High Osteoprotegerin:RANKL Ratios in Synovial Fluid Correlate with the Presence of Calcium Pyrophosphate Crystals
Ian Chang¹, Daisy Obiora², Ann Rosenthal³ and Charlene J. Williams⁴, ¹Medicine/Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ²Urology, Cooper Hospital, Camden, NJ, ³Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁴Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ
Background/Purpose: Calcium pyrophosphate deposition disease (CPDD) is a common cause of both acute and chronic arthritis in the elderly. It is estimated that twenty percent…
Abstract Number: 1435 • 2017 ACR/ARHP Annual Meeting
Consistent Inhibition of Joint Destruction By Denosumab in Important Subgroups of Japanese Patients with Rheumatoid Arthritis: Pooled Analysis of Phase 2 and 3 Studies
Yoshiya Tanaka¹, Tsutomu Takeuchi², Satoshi Soen³, Naoki Ishiguro⁴, Hisashi Yamanaka⁵, Toshiyuki Yoneda⁶, Sakae Tanaka⁷, Takaya Nitta⁸, Naoki Okubo⁹, Harry K. Genant¹⁰ and Désirée van der Heijde¹¹, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³Kindai University Nara Hospital, Ikoma, Japan, ⁴Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁵Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁶Indiana University School of Medicine, Indianapolis, IN, ⁷Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Bunkyo-ku, Japan, ⁸Daiichi Sankyo Co., Ltd., Tokyo, Japan, ⁹DaiichiSankyo CO., LTD., Tokyo, Japan, ¹⁰University of California, San Francisco, CA, ¹¹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Denosumab is a fully human monoclonal antibody (IgG2 subclass) that inhibits bone resorption by blocking RANKL. Phase 2 (DRIVE) and phase 3 (DESIRABLE) studies…
Abstract Number: 1792 • 2017 ACR/ARHP Annual Meeting
Distinct and Overlapping Activities of IL-17A and TNF on the Expression of Proinflammatory Cytokines and MMPs in Psoriatic Arthritis: Rationale for Anti-IL-17A/Anti-Tnfalpha Combination Therapy?
Xiaofei Xu¹, Nadine Davelaar², Anne-Marie Otten-Mus³, Patrick Asmawidjaja², J.M.W. Hazes⁴, Dominique Baeten⁵, Marijn Vis⁶, Radjesh Bisoendial¹ and Erik Lubberts², ¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ²Rheumatology and Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ³Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Department of Rheumatology, Erasmus University Medical Centre, Rotterdam, Netherlands, ⁵Clinical Immunology and Rheumatology/Experimental immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁶Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands
Background/Purpose: TNF and IL-17A are proinflammatory cytokines critically involved in the pathogenesis of psoriatic arthritis (PsA). Currently, targeting TNF is the first choice of a…
Abstract Number: 325 • 2016 ACR/ARHP Annual Meeting
Ebselen Is a Potential Anti-Osteoporosis Agent By Suppressing RANK Ligand-Induced Osteoclast Differentiation in Vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In Vivo
Changhoon Lee¹, Jong Min Baek², Ju-Young Kim², Won-Seok Lee³, Wan-Hee Yoo⁴, Myeung Su Lee⁵ and ACR authors group, ¹Division of Rheumatology, Department of Internal Medicine, Wonkwang University Hospital, Iksan, Korea, The Republic of, ²Department of Anatomy, School of Medicine, Wonkwang University, Iksan, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine of Chonbuk National University Hospital-Chonbuk National University, jeonju, South Korea, ⁴Division of Rhuematology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine of Chonbuk National University Hospital-Chonbuk National University, Jeonju, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Wonkwang University Hospital, Iksan, Chonbuk, South Korea
Background/Purpose: Ebselen is a non-toxic seleno-organic drug with anti-inflammatory and antioxidant properties that is currently being examined in clinical trials to prevent and treat various diseases,…
Abstract Number: 358 • 2016 ACR/ARHP Annual Meeting
Increased Infection Risk with Concomitant Use of RANK Ligand-Inhibitor, Denosumab and TNF-Inhibitors or Other Biologics: Reality or Illusion? Long Term Experience at the University of Southern California
Purva Chhibar¹ and Glenn Ehresmann², ¹Internal Medicine, Division of Rheumatology, University of Southern California, Keck School of Medicine of USC, Los Angeles, CA, ²Internal Medicine, Division of Rheumatology, University of Southern Californnia, Keck School of Medicine of USC, Los Angeles, CA
Background/Purpose: Patients with autoimmune diseases are at increased risk of early onset osteoporosis due to multiple reasons including prolonged exposure to corticosteroids and the disease…
Abstract Number: 471 • 2016 ACR/ARHP Annual Meeting
Epstein-Barr Virus-Induced Expression of Receptor Activator Nuclear Factor-κb Ligand on B Cells Is Possibly Responsible for Erosive Arthritis in Epstein-Barr Virus-Infected Humanized Nonobese Diabetic/Shi-Scid/γcnull Mice
Mitsuhiro Iwata¹, Yosuke Nagasawa¹, Noboru Kitamura¹, Takamasa Nozaki¹, Eiko Ishizuka¹, Ken-Ichi Imadome², Shigeyoshi Fujiwara³ and Masami Takei¹, ¹Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Division of Advanced Medicine for Virus Infections, National Research Institute for Child Health and Development, Tokyo, Japan, ³Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan
Background/Purpose: Humanized nonobese diabetic/Shi-scid/γcnull (NOG) mice, which are reconstituted with human hematoimmune system by transplantation with human CD34＋ hematopoietic stem cells (termed as humanization), have…
Abstract Number: 926 • 2016 ACR/ARHP Annual Meeting
Increased Concentration of Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Predate Onset of Rheumatoid Arthritis
Linda Johansson¹, Lisbeth Ärlestig¹, Heidi Kokkonen² and Solbritt Rantapaa-Dahlqvist³, ¹Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ²Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, ³Umeå University, Department of Public Health and Clinical Medicine/ Rheumatology, Umeå, Sweden
Background/Purpose: Receptor activator of nuclear factor κB ligand (RANKL) an important regulator of bone metabolism has a key role in local bone destruction and osteoporosis…
Abstract Number: 1656 • 2016 ACR/ARHP Annual Meeting
Compare the Potential of Osteoclast Precursors (OCPs) Residing in Bone Marrow and Peripheral Blood As the Surrogates of Psoriasis Pathogenesis
Yahui Grace Chiu¹, Edward Schwarz², Dongge Li³, Nelson Huertas³, Cristy Bell⁴, Debbie Campbell⁴ and Christopher T. Ritchlin⁵, ¹Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Orthopedeatrics, University of Rochester, Rochester, NY, ³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁴Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁵Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Bone marrow (BM) is not only the place where osteoclast precursors (OCPs) are derived from, but also the major reservoirs of OCPs. Current data…
Abstract Number: 2140 • 2016 ACR/ARHP Annual Meeting
Phenotypic and Functional Characteristics of Exosomes Isolated from Human Osteoarthritis (OA) Synovial Fluid
Geraldine M. McCarthy¹, Dylan McGagh², Clare C. Cunningham³, Emma M. Corr⁴, Louise Sullivan⁵, Fatima Haji⁶ and Aisling Dunne⁴, ¹Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ²School of Biochemistry & Immunology and School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, ³School of Biochemistry and Immunology, Trinity College Dublin, Dubln, Ireland, ⁴School of Biochemistry and Immunology, Trinity College Dublin, Dublin 2, Ireland, ⁵Trinity Biomedical Sciences Institute, Trinity College Dublin, School of Biochemistry & Immunology and School of Medicine, Dublin 2, Ireland, ⁶Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland
Background/Purpose: Exosomes are biologically active microvesicles derived from the endosomal membrane system understood to play a significant role in a wide range of inflammatory diseases.…
Abstract Number: 2271 • 2016 ACR/ARHP Annual Meeting
Mutation in Osteoprotegerin Gene: Early-Onset Osteoarthritis and Chondrocalcinosis in a US Family of Italian/German Ancestry
Urooj Qazi¹, Charlene J. Williams², Mark L. Bernstein³, Aaron Charniak⁴, Amaryllis Ortiz², Ann K. Rosenthal⁵, Lucien Cardinal¹ and Alan T. Kaell¹, ¹Internal Medicine, SUNY Stony Brook Medicine-John T Mather Memorial Hospital, Port Jefferson, NY, ²Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ, ³Rheumatology, SUNY Stony Brook Medicine-John T Mather Memorial Hospital, Stony Brook, NY, ⁴SUNY Stony Brook Medicine-John T Mather Memorial Hospital, Port Jefferson, NY, ⁵Division of Rheumatology, Medical College of WI, Milwaukee, WI
Background/Purpose: Chondrocalcinosis is characterized by calcium pyrophosphate dihydrate (CPPD) deposition in articular cartilage. It can occur as a rare autosomal dominant disorder with florid early-onset…
Abstract Number: 2506 • 2016 ACR/ARHP Annual Meeting
Seropositivity Predicts Bone Biomarker Change in an Inception Cohort of Rheumatoid Arthritis Patients Treated-to-Target with Combination Conventional DMARD Therapy
Mihir D. Wechalekar^1,2, Susan Lester³, Sunil Nagpal⁴, Jessica Peters⁵, Anuk Das⁶, Pravin Hissaria^7,8, Tania Crotti⁹, Llew Spargo¹⁰, Jennifer G Walker^1,2,10, Malcolm D. Smith¹ and Susanna M Proudman^9,10, ¹Flinders University, Adelaide, Australia, ²Rheumatology Unit, Repatriation General Hospital, Adelaide, Australia, ³Rheumatology, Queen Elizabeth Hospital, Woodville South, Australia, ⁴Immunology, Janssen Research & Development, Spring House, PA, ⁵Janssen Research & Development, Spring House, PA, ⁶Janssen R&D, Berwyn, PA, ⁷Royal Adelaide Hospital, Adelaide, Australia, ⁸Immunology, SA Pathology, Adelaide, Australia, ⁹University of Adelaide, Adelaide, Australia, ¹⁰Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: There are limited data regarding the role of and response to treatment, of bone biomarkers in early rheumatoid arthritis (RA) treated with conventional DMARDs.…
Abstract Number: 2582 • 2016 ACR/ARHP Annual Meeting
N-Acetylcysteine Regulates Osteoclastogenesis and Th17 Cell Differentiation in Rheumatoid Arthritis
Kyung-Ann Lee¹, Hae-Rim Kim², Sang Heon Lee³, Bomi Kim⁴ and Kyoung-Woon Kim⁵, ¹Department of Nuclear medicine, Konkuk University Medical center, seoul, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Konkuk University Medical Center, Seoul, Korea, The Republic of, ³Department of Internal Medicine,Division of Rheumatology., Division of Rheumatology, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea, The Republic of, ⁴Convergent Research Consortium for Immunologic disease, St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ⁵Dept of Internal Medicine, Konkuk University Hospital, Seoul, South Korea
Background/Purpose: This study aimed to determine the regulatory role of N-Acetyl-L-cysteine (NAC), an antioxidant, in T cell and osteoclast differentiation in rheumatoid arthritis (RA). Methods:…
Abstract Number: 2716 • 2015 ACR/ARHP Annual Meeting
Dysregulated Osteoclastogenesis Is Related to Natural Killer T Cell Dysfunction in Rheumatoid Arthritis
Seung-Jung Kee¹, Hye Mi Jin², Jeong-Hwa Kang², Young-Nan Cho², Ki-Jeong Park², Hyun-Ju Jung² and Yong-Wook Park², ¹Laboratory Medicine, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ²Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea
Background/Purpose: The aims of the present study were to investigate the role played by natural killer T (NKT) cells in osteoclastogenesis and their effects on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].